| BNT162b2 vaccine booster and mortality due to Covid-19 R Arbel, A Hammerman, R Sergienko, M Friger, A Peretz, D Netzer, ... New England Journal of Medicine 385 (26), 2413-2420, 2021 | 413 | 2021 |
| Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge R Arbel, Y Wolff Sagy, M Hoshen, E Battat, G Lavie, R Sergienko, M Friger, ... New England Journal of Medicine 387 (9), 790-798, 2022 | 412 | 2022 |
| Real-world effectiveness of a single dose of mpox vaccine in males Y Wolff Sagy, R Zucker, A Hammerman, H Markovits, NG Arieh, ... Nature Medicine 29 (3), 748-752, 2023 | 207 | 2023 |
| Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study R Arbel, A Peretz, R Sergienko, M Friger, T Beckenstein, H Duskin-Bitan, ... The Lancet Infectious Diseases 23 (8), 914-921, 2023 | 172 | 2023 |
| Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years R Arbel, R Sergienko, M Friger, A Peretz, T Beckenstein, S Yaron, ... Nature medicine 28 (7), 1486-1490, 2022 | 163 | 2022 |
| Method and system for cardiovascular system diagnosis R Arbel, Y Tal, M Ortenberg US Patent App. 11/489,721, 2007 | 142 | 2007 |
| Effectiveness of the BNT162b2 vaccine after recovery from Covid-19 A Hammerman, R Sergienko, M Friger, T Beckenstein, A Peretz, D Netzer, ... New England Journal of Medicine 386 (13), 1221-1229, 2022 | 140 | 2022 |
| Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation R Arbel, R Sergienko, A Hammerman, S Greenberg-Dotan, E Batat, ... The American Journal of Medicine 132 (7), 847-855. e3, 2019 | 98 | 2019 |
| Bariatric metabolic surgery vs glucagon-like peptide-1 receptor agonists and mortality D Dicker, YW Sagy, N Ramot, E Battat, P Greenland, R Arbel, G Lavie, ... JAMA network open 7 (6), e2415392-e2415392, 2024 | 53 | 2024 |
| Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis J Azuri, A Hammerman, E Aboalhasan, B Sluckis, R Arbel Diabetes, Obesity and Metabolism 25 (4), 961-964, 2023 | 49 | 2023 |
| Prediction of short-term atrial fibrillation risk using primary care electronic health records R Nadarajah, J Wu, D Hogg, K Raveendra, YM Nakao, K Nakao, R Arbel, ... Heart 109 (14), 1072-1079, 2023 | 40 | 2023 |
| Method and system for cardiovascular system diagnosis R Arbel, Y Tal, M Ortenberg US Patent 7,771,364, 2010 | 39 | 2010 |
| Method and system for cardiovascular system diagnosis R Arbel, Y Tal, M Ortenberg US Patent App. 11/892,256, 2008 | 35 | 2008 |
| Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study D Yamin, M Yechezkel, R Arbel, T Beckenstein, R Sergienko, ... The Lancet Infectious Diseases 23 (10), 1130-1142, 2023 | 29 | 2023 |
| Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis J Azuri, A Hammerman, E Aboalhasan, B Sluckis, R Arbel Obesity 31 (6), 1510-1513, 2023 | 26 | 2023 |
| Effectiveness of a single-dose modified vaccinia Ankara in human monkeypox: an observational study R Arbel, YW Sagy, R Zucker, NG Arieh, H Markovits, W Abu-Ahmad, ... Research Square, 2022 | 23 | 2022 |
| Vaccinations versus lockdowns to prevent COVID-19 mortality R Arbel, J Pliskin Vaccines 10 (8), 1347, 2022 | 19 | 2022 |
| PCSK9 inhibitors may improve cardiovascular outcomes—Can we afford them? R Arbel, A Hammerman, N Triki, D Greenberg International Journal of Cardiology 220, 242-245, 2016 | 19 | 2016 |
| Prediction models for heart failure in the community: A systematic review and meta‐analysis R Nadarajah, T Younsi, E Romer, K Raveendra, YM Nakao, K Nakao, ... European Journal of Heart Failure 25 (10), 1724-1738, 2023 | 18 | 2023 |
| Risk assessment of human mpox infections: retrospective cohort study R Zucker, G Lavie, Y Wolff-Sagy, N Gur-Arieh, H Markovits, W Abu-Ahmad, ... Clinical Microbiology and Infection 29 (8), 1070-1074, 2023 | 18 | 2023 |
Ariel HammermanHealth Technology Assessment Director, Medison PharmaVerified email at medisonpharma.com
